Skip to content

Option Care Health

US · OPCH #2386 by market cap Listed 1970
31.01 +0.01 +0.03%
Live - 5344 symbols - heartbeat 304s ago · 2026-10-08 07:31
Pre-market 31.01 0.00%
After-hours 31.04 +0.10%
Overnight 30.71 -0.97%
Market cap
4.65B
P/B
3.69
EPS
1.27
Reader sentiment Are you bullish or bearish on OPCH?

Anonymous reader poll. Unscientific, not investment advice.

✦ Quant Fair Value how this is computed

Near fair value
21.01 fair value ≈ 36.47 51.93
  • Implied fair-value range of 21.01-51.93, from this stock's own trailing 5-year average P/E applied to trailing EPS.
  • Current price is -15.0% below the average-multiple fair value of 36.47.

Valuation each multiple against its own 5-year range

P/B ratio 3.69 In line with history 35th percentile
5-year average 3.78 · #25 of 40 in Medical Care Facilities
P/E ratio 23.48 In line with history 37th percentile
5-year average 28.72 · forward 19.27 · #19 of 30 in Medical Care Facilities
P/S ratio 0.82 Cheap vs history 14th percentile
5-year average 1.17 · forward 0.78 · #22 of 50 in Medical Care Facilities

Vs. peers Medical Care Facilities

Company Market cap P/E (TTM) P/B Div yield
Option Care Health (OPCH) 4.65B 23.49 3.69 0.00%
HCA Healthcare (HCA) 95.08B 14.73 -14.32 0.68%
Tenet Healthcare (THC) 20.92B 10.04 4.49 0.00%
Encompass Health (EHC) 12.08B 19.95 4.65 0.62%
DaVita (DVA) 11.28B 14.57 -14.74 0.00%
Fresenius Medical Care (FMS) 11.01B 11.14 0.78 4.13%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★★★ Fair value31.05 Economic moatNone UncertaintyMedium

Trading 0.1% below Morningstar's fair value estimate.

Fair value

Option Care Health Inc earns a 5-star quantitative star rating, indicating our belief that this share class offers a compelling opportunity for investors. The stock currently trades at a 25% discount to our quantitative fair value estimate of $31.05 per share; however, some caution is warranted due to this estimate's medium uncertainty rating.

The company's profitability bolsters our estimated valuation. Highly profitable companies are often more resilient in recessions and are likely to generate stronger future cash flows for shareholders. For example, the firm's earnings yield of 7.8% lies in the top 30% globally. This suggests that it is generating substantial earnings relative to its share price, which contributes to our view that shares are undervalued.

The firm's valuation metrics are an additional encouraging factor. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. The firm's enterprise value to market value ratio of 1.3, for example, sits in the top 30% compared with peers globally. While highly leveraged firms can be risky, they can also be highly rewarding. This company's high enterprise value relative to its market value suggests that wise investments will yield outsize returns for investors. This characteristic further promotes our favorable price/fair value ratio.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has been a laggard relative to the broader universe over the past year. This underperformance makes the stock appear cheap, which portends a buying opportunity in light of other contributors to our model.

Economic moat

With its quantitative economic moat rating of none, we do not expect this company to materially outearn its cost of capital in the long run. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-10-08 07:31:28 · For reference only, not investment advice and not tailored to your situation.